14 completed, 1 recruiting, 1 unknown, 1 withdrawn. 17 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 17 | Completed 14, Recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 2 | Completed 2 |
Follow trebananib: new trials by email Literature Review of trebananib trials Research Report on trebananib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma AMG 386, Docetaxel - Urothelial Carcinoma | Phase 2 | Withdrawn | University of Colorado, Denver | 2014-02-01 | 2014-04-29 | |
| Phase 1b/2 Trial of AMG386 With Pemetrexed and Carboplatin in Non-Small Cell Lung Cancer AMG 386, AMG 386 Placebo, Pemetrexed - Non Small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | Amgen | 36 | 2012-08-01 | 2016-06-03 |
| Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate - Advanced Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 41 | 2012-08-01 | 2022-06-07 |
| Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery Laboratory Biomarker Analysis, Trebananib - Adult Angiosarcoma, Recurrent Adult Soft Tissue Sarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 16 | 2012-07-01 | 2015-10-19 |
| Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors Bevacizumab, Laboratory Biomarker Analysis, Pharmacological Study - Giant Cell Glioblastoma, Glioblastoma | Phase 2 | Completed | National Cancer Institute (NCI) | 137 | 2012-06-04 | 2022-07-21 |
| AMG 386 and Abiraterone for Advanced Prostate Cancer AMG 386, Abiraterone, Prednisone - Prostatic Neoplasms, Prostate Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 36 | 2012-02-08 | 2019-03-05 |
| Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer Trebananib - Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma | Phase 2 | Completed | Gynecologic Oncology Group | 35 | 2011-06-06 | 2018-02-23 |
| Amgen 386 for Recurrent Glioblastoma Amgen 386, Bevacizumab - Glioblastoma Multiforme | Phase 1 / Phase 2 | Completed | Dana-Farber Cancer Institute | 48 | 2010-12-01 | 2017-07-02 |
| Dual Targeting of Vascular Endothelial Growth Factor-A Together With Angiopoietins in Chemotherapy-naïve Metastatic Colorectal Cancer AMG386 and bevacizumab - Metastatic Colorectal Cancer | Phase 2 | Unknown | Austin Health | 40 | 2010-11-01 | 2010-11-30 |
| I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin - Breast Neoplasms, Breast Cancer | Phase 2 | Recruiting | QuantumLeap Healthcare Collaborative | 5000 | 2010-03-01 | 2026-05-06 |
| A Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advanced or Inoperable Hepatocellular Cancer AMG 386, Sorafenib - Advanced Hepatocellular Carcinoma, Inoperable Hepatocellular Carcinoma | Phase 2 | Completed | Amgen | 60 | 2009-08-01 | 2016-04-04 |
| AMG 386 Phase 2 Open-Label Renal Cell Carcinoma (RCC) Study 1st Line or After Cytokine Failure in Combination With Sunitinib Sunitinib, Trebananib - Advanced Renal Cell Carcinoma | Phase 2 | Completed | Amgen | 85 | 2009-05-28 | 2020-07-01 |
| A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma AMG 386, AMG 386 Placebo, FOLFIRI - Cancer, Carcinoma | Phase 2 | Completed | Amgen | 144 | 2008-11-01 | 2015-09-02 |
| Phase 2 Study of AMG 386 (20060439) in Combination With Cisplatin & Capecitabine in Subjects With Metastatic Gastric, Gastroesophageal Junction, or Distal Esophageal Adenocarcinoma AMG 386 placebo, AMG 386 10mg/kg, AMG 386 3mg/kg - Gastrointestinal Cancer | Phase 2 | Completed | Amgen | 171 | 2007-12-01 | 2014-05-07 |
| Phase 2 AMG 386 in Comb. Paclitaxel for Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer AMG 386, Paclitaxel, AMG 386 Placebo - Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Completed | Amgen | 161 | 2007-07-05 | 2019-12-18 |
| Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients AMG 386 Placebo, AMG 386, Bevacizumab - Locally Recurrent and Metastatic Breast Cancer | Phase 2 | Completed | Amgen | 228 | 2007-07-01 | 2015-10-29 |
| AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib AMG 386, Sorafenib, AMG 386 placebo IV - Advanced Renal Cell Carcinoma | Phase 2 | Completed | Amgen | 152 | 2007-05-01 | 2016-03-23 |
Brain Neoplasms (2) · Breast Neoplasms (2) · Carcinoma, Renal Cell (2) · Colorectal Neoplasms (2) · Gastrointestinal Neoplasms (2) · Glioblastoma (2) · Hemangiosarcoma (2) · Neoplasm Metastasis (2) · Neoplasms (2) · Carcinoma (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Transitional Cell (1) · Colonic Neoplasms (1) · Fallopian Tube Neoplasms (1) · Glioma (1)
Amgen (8) · National Cancer Institute (NCI) (4) · Austin Health (1) · Dana-Farber Cancer Institute (1) · Gynecologic Oncology Group (1) · QuantumLeap Healthcare Collaborative (1) · University of Colorado, Denver (1)
United States (9) · Australia (3) · Belgium (2) · Canada (2) · Spain (2) · Austria (1) · Denmark (1) · Finland (1) · France (1) · Greece (1) · Hungary (1) · India (1) · Netherlands (1) · Poland (1) · United Kingdom (1)
David Reardon, MD (1) · Eudocia Q Lee (1) · Kathleen Moore (1) · Laura Esserman, MD, MBA (1) · Niall Tebbutt (1) · Ravi A Madan, M.D. (1) · Sandra D'Angelo (1) · Thomas Flaig, MD (1) · Thomas J Semrad (1)
PMID 21796368, PMID 22198468, PMID 22623692, PMID 22649152, PMID 22692704, PMID 23361051, PMID 25747197, PMID 26304872, PMID 27406346, PMID 27406347, PMID 28592620, PMID 28851423, PMID 32031889, PMID 32053137, PMID 32154928, PMID 32450725, PMID 32701140, PMID 34529000, PMID 34741021, PMID 35623341, PMID 35993306, PMID 36069821, PMID 36456573, PMID 37029329, PMID 37185961, PMID 37325931, PMID 37505107, PMID 38086377, PMID 38180338, PMID 38745646, PMID 39158353, PMID 39277671, PMID 39277672, PMID 39613746, PMID 39625569, PMID 40526879, PMID 40551254, PMID 40639409, PMID 40679371, PMID 40777112, PMID 41879562, PMID 42530945, PMID 42545411, PMID 42619946, PMID 42811224
U10CA180868 (2), N01CM00038 (1), P30CA033572 (1), U10CA021661 (1), U10CA027469 (1), U10CA031946 (1), U10CA180821 (1)